Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment ...

With the blessing of US regulator FDA, Paradigm Biopharma hopes to launch its pivotal trial of its knee osteoarthritis drug candidate.

That’s why we all work at Terray,” said Jacob Berlin, Ph.D, co-founder and CEO of Terray Therapeutics. “Knowledge of what ...

However, on October 11, the CME FedWatch tool showed that 89.5% of the market now expects a 25 bps rate cut and the rest ...

SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar ...

According to the researchers, their deep-learning framework identified several gut microbiome-derived metabolites along with ...

In propensity score-matched cohorts of 121,046 hospitalized patients, those with RA and T2D had an ILD prevalence of 2.25%, ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Virios Combines with Wex Pharmaceuticals to Form Dogwood Therapeutics ...

Jaguar Health, Inc. (NASDAQ:JAGX) (”Jaguar” or the “Company”) today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 ...

(Image Credits: Pixabay) Sage Therapeutics on Tuesday announced that it would discontinue the development of its experimental drug for Alzheimer’s disease. According to the company’s statement ...

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa ...

GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to ...